{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:46:28Z","timestamp":1791744388868,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in cancer therapeutics, particularly targeted agents and tissue agnostic immunotherapies, have transformed care while introducing new challenges in cardiovascular safety. Although clinical guidelines have evolved, regulatory processes critical to ensuring safe innovation remain under-leveraged and often disconnected from real-world implementation. This gap is especially concerning amid federal downsizing, which has led to significant staff reductions at the United States Food and Drug Administration (FDA) and other health agencies. To meet growing needs in patient safety and therapeutic oversight, a new paradigm is emerging-one that is collaborative, adaptive, and inclusive of all stakeholders. Drug manufacturers, oncologists, cardiologists, clinical trialists, regulators, and technology developers must integrate around shared goals. Cardiovascular endpoints should be integrated into pre\u2013new drug application (NDA) studies, with trial designs that include at-risk populations and robust cardiac monitoring. Early detection tools and mitigation strategies should be co-developed when feasible alongside therapeutics and considered part of the approval process.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Integrated framework for drug-associated cardiotoxicity across the therapeutic lifecycle. The illustration highlights three essential domains: (1) Drug development, including predictive modeling, preclinical assessment, and structured clinical trials; (2) Patient care, incorporating surveillance and management strategies to mitigate cardiotoxicity risk; and (3) Regulatory activity, emphasizing safety evaluation and guideline development. This framework reflects the multidimensional process required to detect, manage, and prevent cardiotoxicity associated with cancer therapeutics.<\/jats:p>","DOI":"10.1007\/s11239-026-03282-8","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:16:40Z","timestamp":1781065000000},"page":"1817-1824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advancing cancer therapeutics: new perspectives on mechanisms, regulatory and policy challenges, and innovative multi-modality strategies for the early detection of cardiotoxicity"],"prefix":"10.1007","volume":"59","author":[{"given":"Richard C.","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"4","key":"3282_CR1","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaccao.2025.03.008","volume":"7","author":"FI Mulder","year":"2025","unstructured":"Mulder FI et al (2025) Risk of cardiovascular disease in cancer survivors after systemic treatment. JACC CardioOncol 7(4):360\u2013378","journal-title":"JACC CardioOncol"},{"key":"3282_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.5785","author":"D Shyr","year":"2026","unstructured":"Shyr D et al (2026) Clonal hematopoiesis and cardiovascular disease risk after cancer therapy in patients with solid tumors. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2025.5785","journal-title":"JAMA Oncol"},{"key":"3282_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.847012","volume":"9","author":"MB Morelli","year":"2022","unstructured":"Morelli MB et al (2022) Cardiotoxicity of anticancer drugs: molecular mechanisms and strategies for cardioprotection. Front Cardiovasc Med 9:847012","journal-title":"Front Cardiovasc Med"},{"key":"3282_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.maturitas.2017.05.014","volume":"105","author":"W Naaktgeboren","year":"2017","unstructured":"Naaktgeboren W et al (2017) Long-term cardiovascular health in adult cancer survivors. Maturitas 105:37\u201345","journal-title":"Maturitas"},{"issue":"1","key":"3282_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1136\/heartjnl-2024-325309","volume":"112","author":"L Szabo","year":"2026","unstructured":"Szabo L et al (2026) Cardiovascular disease burden and risk factor management in cancer survivors: insights into a multiethnic, socioeconomically deprived urban population. Heart 112(1):37\u201345","journal-title":"Heart"},{"issue":"6","key":"3282_CR6","doi-asserted-by":"publisher","first-page":"e2216191","DOI":"10.1001\/jamanetworkopen.2022.16191","volume":"5","author":"K Jenei","year":"2022","unstructured":"Jenei K (2022) The timing of cancer drug approvals in the United States and Europe. JAMA Netw Open 5(6):e2216191\u2013e2216191","journal-title":"JAMA Netw Open"},{"issue":"4","key":"3282_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/1468-0009.12476","volume":"98","author":"M Salcher\u2010Konrad","year":"2020","unstructured":"Salcher\u2010Konrad M, Naci H, Davis C (2020) Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. Milbank Q 98(4):1219\u20131256","journal-title":"Milbank Q"},{"issue":"1","key":"3282_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11864-025-01366-w","volume":"27","author":"R Mszar","year":"2026","unstructured":"Mszar R et al (2026) Research priorities and future directions in cardio-oncology. Curr Treat Options Oncol 27(1):4","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"3282_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.hlc.2024.01.013","volume":"33","author":"L Balachandran","year":"2024","unstructured":"Balachandran L et al (2024) Cancer therapies and cardiomyocyte viability: which drugs are directly cardiotoxic? Heart Lung Circ 33(5):747\u2013752","journal-title":"Heart Lung Circ"},{"issue":"1","key":"3282_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12170-025-00777-6","volume":"19","author":"A Verma","year":"2025","unstructured":"Verma A et al (2025) Cardiac toxicities of cancer therapies: from traditional agents to emerging targets in cardio-oncology. Curr Cardiovasc Risk Rep 19(1):25","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"3282_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1726458","volume":"16","author":"Y Zhang","year":"2026","unstructured":"Zhang Y et al (2026) Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors. Front Pharmacol 16:1726458","journal-title":"Front Pharmacol"},{"key":"3282_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2025.102662","volume":"64","author":"Y Liu","year":"2026","unstructured":"Liu Y et al (2026) CAR-T therapy in non-small cell lung cancer: clinical prospects, potential, and strategies for cardiotoxicity management. Transl Oncol 64:102662","journal-title":"Transl Oncol"},{"issue":"24","key":"3282_CR13","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1136\/heartjnl-2022-321324","volume":"109","author":"Z Raisi-Estabragh","year":"2023","unstructured":"Raisi-Estabragh Z et al (2023) Burden and prognostic impact of cardiovascular disease in patients with cancer. Heart 109(24):1819\u20131826","journal-title":"Heart"},{"key":"3282_CR14","doi-asserted-by":"crossref","unstructured":"Liu F et al (2026) Association between the oxidative balance score and all-cause mortality in patients with cardiovascular disease-cancer comorbidity. J Health Popul Nutr","DOI":"10.1186\/s41043-025-01213-6"},{"issue":"1","key":"3282_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/RTI.0000000000000853","volume":"41","author":"MD Cham","year":"2026","unstructured":"Cham MD, Shemesh J (2026) Incidental cardiovascular findings in lung cancer screening and noncontrast chest computed tomography. J Thorac Imaging 41(1):e0853","journal-title":"J Thorac Imaging"},{"key":"3282_CR16","doi-asserted-by":"crossref","unstructured":"Li W et al (2026) Lipid metabolism\u2013inflammation crosstalk and risk of incident cancer, cardiovascular diseases, and stroke among individuals with prediabetes: findings from a nationwide, population based, prospective cohort study. Diabetol Metab Syndr","DOI":"10.1186\/s13098-025-02065-0"},{"issue":"1","key":"3282_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2024.06.006","volume":"7","author":"A Blaes","year":"2025","unstructured":"Blaes A et al (2025) Cardiovascular considerations after cancer therapy: gaps in evidence and JACC: CardioOncology expert panel recommendations. Cardiooncology 7(1):1\u201319","journal-title":"Cardiooncology"},{"issue":"1","key":"3282_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s40273-023-01320-4","volume":"42","author":"DT Michaeli","year":"2024","unstructured":"Michaeli DT, Michaeli T (2024) Launch and post-launch prices of injectable cancer drugs in the US: clinical benefit, innovation, epidemiology, and competition. Pharmacoeconomics 42(1):117\u2013131","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"3282_CR19","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1016\/S1470-2045(23)00592-2","volume":"25","author":"SN Koole","year":"2024","unstructured":"Koole SN et al (2024) Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications. Lancet Oncol 25(3):e126\u2013e135","journal-title":"Lancet Oncol"},{"issue":"17","key":"3282_CR20","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jama.2024.2396","volume":"331","author":"IT Liu","year":"2024","unstructured":"Liu IT, Kesselheim AS, Cliff ERS (2024) Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval. JAMA 331(17):1471\u20131479","journal-title":"JAMA"},{"issue":"1","key":"3282_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1200\/JCO.23.01779","volume":"43","author":"G Bostany","year":"2025","unstructured":"Bostany G et al (2025) Cardiac dysfunction among breast cancer survivors: role of cardiotoxic therapy and cardiovascular risk factors. J Clin Oncol 43(1):32\u201345","journal-title":"J Clin Oncol"},{"issue":"10","key":"3282_CR22","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","volume":"26","author":"CG Tocchetti","year":"2024","unstructured":"Tocchetti CG et al (2024) Cardiovascular toxicities of immune therapies for cancer\u2013a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail 26(10):2055\u20132076","journal-title":"Eur J Heart Fail"},{"key":"3282_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae279","author":"RS Herbst","year":"2024","unstructured":"Herbst RS et al (2024) Optimizing public-private partnerships to support clinical cancer research. JNCI J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djae279","journal-title":"JNCI J Natl Cancer Inst"},{"key":"3282_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.101069","author":"A Lala","year":"2025","unstructured":"Lala A et al (2025) The continuum of prevention and heart failure in cardiovascular medicine: a joint scientific statement from the Heart Failure Society of America and The American Society for Preventive Cardiology. J Card Fail. https:\/\/doi.org\/10.1016\/j.ajpc.2025.101069","journal-title":"J Card Fail"},{"issue":"15","key":"3282_CR25","doi-asserted-by":"publisher","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","volume":"145","author":"CJ Beavers","year":"2022","unstructured":"Beavers CJ et al (2022) Cardio-oncology drug interactions: a scientific statement from the American Heart Association. Circulation 145(15):e811\u2013e838","journal-title":"Circulation"},{"issue":"7","key":"3282_CR26","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1056\/NEJMra1602972","volume":"376","author":"AL Gassman","year":"2017","unstructured":"Gassman AL, Nguyen CP, Joffe HV (2017) FDA regulation of prescription drugs. N Engl J Med 376(7):674\u2013682","journal-title":"N Engl J Med"},{"issue":"5","key":"3282_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1200\/OP.20.00924","volume":"17","author":"JR Stone","year":"2021","unstructured":"Stone JR et al (2021) Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations. JCO Oncol Pract 17(5):228\u2013236","journal-title":"JCO Oncol Pract"},{"issue":"4","key":"3282_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J et al (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43(4):280\u2013299","journal-title":"Eur Heart J"},{"key":"3282_CR29","doi-asserted-by":"crossref","unstructured":"Leong DP, Mukherjee SD (2023) The European society of cardiology cardio-oncology guidelines: evidence base, actionability, and relevance to clinical practice. American College of Cardiology Foundation Washington DC. p. 137\u2013140","DOI":"10.1016\/j.jaccao.2022.10.009"},{"key":"3282_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/B978-0-443-29829-5.00013-X","volume-title":"Innovations in Cardio-Oncology","author":"RR Cullinane","year":"2025","unstructured":"Cullinane RR et al (2025) Medical society guidelines in cardio-oncology. Innovations in Cardio-Oncology. Elsevier, pp 495\u2013524"},{"key":"3282_CR31","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2023.49","volume":"20","author":"S Quick","year":"2025","unstructured":"Quick S et al (2025) Interdisciplinary management of cardiotoxicity in outpatient settings: A survey on practices, perceptions and potential for improvement. Eur Cardiol Rev 20:e02","journal-title":"Eur Cardiol Rev"},{"issue":"15","key":"3282_CR32","doi-asserted-by":"publisher","first-page":"e926","DOI":"10.1161\/CIR.0000000000001308","volume":"151","author":"TD Ryan","year":"2025","unstructured":"Ryan TD et al (2025) Cardiovascular toxicity in patients treated for childhood cancer: A scientific statement from the American Heart Association. Circulation 151(15):e926\u2013e943","journal-title":"Circulation"},{"key":"3282_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3636","author":"A Ghigo","year":"2025","unstructured":"Ghigo A et al (2025) Update on preclinical models of cancer therapy\u2010related cardiac dysfunction: challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio\u2010Oncology, and the ESC Working Group on Cellular Biology of the Heart. Eur J Heart Fail. https:\/\/doi.org\/10.1002\/ejhf.3636","journal-title":"Eur J Heart Fail"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03282-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:36:51Z","timestamp":1791743811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03282-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":33,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3282"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03282-8","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}